Johnson & Johnson To Push Diabetes Management Model
This article was originally published in PharmAsia News
Executive SummaryAt the one-year anniversary of the establishment of the Beijing Diabetes Institute (PharmAsia News, Aug. 18, 2008), Johnson & Johnson announced that it will push to improve the prevention and treatment effectiveness of diabetes and its complications. Starting with Shanghai, Zhejiang, Liaoning, Heilongjiang and Chongqing, the project will set up a highly efficient and seamless diabetes management model between hospitals and the community. Since its establishment, the Beijing diabetes institute has conducted four sessions of diabetes educator training courses in China, teaching 173 students from 25 provinces. In line with the country's healthcare reform, the institution this year began to focus on promoting its diabetes management model, which targets early detection and standardized management of the disease. (Click here for more - Chinese language)
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.